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Background: We sought to explore the effect of potent platelet inhibition on recurrent (e.g. second) and ischemic events, such as urgent 
revascularization (Urgent Revasc), (severe) recurrent ischemia (SRI/RI), transient ischemic attacks (TIA) and arterial thromboses (ATE).
Methods: In PLATO, 18,624 patients (pts) presenting with acute coronary syndromes were randomized to ticagrelor vs. clopidogrel with median 
follow-up of 277 days. Kaplan-Meier estimates and Cox proportional hazard models were used to calculate time to first event and hazard ratios. 
Mean number of events were compared using a Poisson regression model.
Results: Among pts taking ticagrelor, there were 1057 total primary endpoint events vs. 1225 in pts on clopidogrel (rate ratio=0.86, p<0.001). 
There was also significant reduction in mean number of events per pt (Figure) and the hazard for time to second occurrence of CVD/MI/Stroke with 
ticagrelor (p<0.001). A parallel risk reduction for first, second and total ischemic events (CVD/MI/Stroke/SRI/RI/TIA/ATE and CVD/MI/Stroke/
Urgent Revascularization) was also observed (p<0.001) (Figure).
Conclusion: Although clinical trials traditionally censor patients after the occurrence of the primary endpoint, recurrent events contribute valuable 
information for the clinician regarding ongoing therapy. In PLATO, treatment with ticagrelor resulted in a highly significant risk reduction in primary, 
secondary and total cardiovascular and ischemic events when compared to clopidogrel.
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